Literature DB >> 8399912

Structural variations and phenotypic switching of mycoplasmal antigens.

H L Watson1, X Zheng, G H Cassell.   

Abstract

It is becoming apparent that a high rate of variability of surface structures is a ubiquitous property among mycoplasmas. The present study demonstrates how variations in the size of the V-1 antigen (a major surface antigen of Mycoplasma pulmonis thought to be associated with virulence) are reflected by phenotypic differences (cytadherence) that may play a role in virulence of the organism. Furthermore, a similar antigen is described for the human pathogen Urea-plasma urealyticum, and data are presented on the analysis of clinical isolates that demonstrate the potential for variation in the size of this antigen in vivo. Although no direct connection of antigen variation to natural disease has yet been presented, the data further document the tremendous potential for virulence-related diversity possessed by these organisms and emphasize the importance of a valid animal model for discerning the true relationship between variation and virulence.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8399912     DOI: 10.1093/clinids/17.supplement_1.s183

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Characterization of a multigene family undergoing high-frequency DNA rearrangements and coding for abundant variable surface proteins in Mycoplasma agalactiae.

Authors:  M D Glew; L Papazisi; F Poumarat; D Bergonier; R Rosengarten; C Citti
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

2.  Spiralin, a mycoplasmal membrane lipoprotein, induces T-cell-independent B-cell blastogenesis and secretion of proinflammatory cytokines.

Authors:  C Brenner; H Wróblewski; M Le Henaff; L Montagnier; A Blanchard
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

3.  A family of phase-variable restriction enzymes with differing specificities generated by high-frequency gene rearrangements.

Authors:  K Dybvig; R Sitaraman; C T French
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

4.  Mycoplasma synoviae has two distinct phase-variable major membrane antigens, one of which is a putative hemagglutinin.

Authors:  A H Noormohammadi; P F Markham; K G Whithear; I D Walker; V A Gurevich; D H Ley; G F Browning
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

5.  Development of monoclonal antibodies against Ureaplasma urealyticum serotypes and their use for serotyping clinical isolates.

Authors:  F Echahidi; G Muyldermans; S Lauwers; A Naessens
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

6.  Resistance of Mycoplasma pulmonis to complement lysis is dependent on the number of Vsa tandem repeats: shield hypothesis.

Authors:  Warren L Simmons; Amy M Denison; Kevin Dybvig
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

7.  The Vsa proteins modulate susceptibility of Mycoplasma pulmonis to complement killing, hemadsorption, and adherence to polystyrene.

Authors:  Warren L Simmons; Kevin Dybvig
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

8.  Production of recombinant antigens of Ureaplasma parvum serotypes 3 and 6 for development of a serological assay.

Authors:  E Vancutsem; F Echahidi; K Van Geel; G Muyldermans; O Soetens; A Naessens
Journal:  Clin Vaccine Immunol       Date:  2007-12-19

9.  Sequence analysis of the chromosomal region around and within the V-1-encoding gene of Mycoplasma pulmonis: evidence for DNA inversion as a mechanism for V-1 variation.

Authors:  W L Simmons; C Zuhua; J I Glass; J W Simecka; G H Cassell; H L Watson
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

10.  The number of direct repeats in hagA is variable among Porphyromonas gingivalis strains.

Authors:  E Kozarov; J Whitlock; H Dong; E Carrasco; A Progulske-Fox
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.